Trevor Clancy new group leader in Cancer Systems Biomedicine

Trevor Clancy is a cancer bioinformatics scientist with over 20 years of experience in bioinformatics, cancer research and biotechnology. Trevor has focused on integrating multi-omics, tumor–immune biology and AI to generate clinically meaningful insight. He co-founded OncoImmunity (later NEC OncoImmunity following its acquisition by the multinational NEC Corporation) and, as Chief Scientific Officer and leading senior scientist, spearheaded AI-driven personalized cancer immunotherapy projects.
His overarching goal now is to develop robust AI-based tools, such as tumor avatars, that improve cancer prevention, therapy selection and patient outcomes.
